Soluble interleukin 2 receptors in patients with malignant lymphoma.
We performed a retrospective analysis of serum interleukin 2 receptor (IL-2R) levels in a group of 35 patients with malignant lymphoma (ML; 13 T cell and 22 B cell) using a new enzyme immunoassay. Our objectives were to determine if elevated levels of soluble IL-2R occur in patients with active ML, whether serum IL-2R levels are prognostic, and whether prospective studies are warranted. Our preliminary data indicate that serum IL-2R levels correlate with disease activity and size of tumor, but not with grade or stage of the tumor. Five-year actuarial survival was 20% for patients with IL-2R levels greater than 1000 U/mL at any time during their course and 86% for patients who did not exceed that threshold. Furthermore, patients with IL-2R levels lower than 1000 U/mL were more likely to achieve a complete remission. Serum lactate dehydrogenase and uric acid levels did not show significant correlation with disease activity or prognosis. We conclude that serum IL-2R levels may have clinical and prognostic significance in patients with ML and that prospective studies are indicated.
Harrington
D S
DS
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha 68105.
Patil
K
K
Lai
P K
PK
Yasuda
N N
NN
Armitage
J O
JO
Ip
S H
SH
Weisenburger
D D
DD
Linder
J
J
Purtilo
D T
DT
D000914:Antibodies, Viral / Q000032:analysis; D001402:B-Lymphocytes; D017977:Deltaretrovirus / Q000276:immunology; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007376:Interleukin-2 / Q000097:blood*; D007564:Japan / Q000208:ethnology; D008223:Lymphoma / Q000097:blood*; D008297:Male; D011971:Receptors, Immunologic / Q000032:analysis*; D015375:Receptors, Interleukin-2; D012189:Retrospective Studies; D012995:Solubility; D013601:T-Lymphocytes
D000914:Antibodies, Viral; D007376:Interleukin-2; D011971:Receptors, Immunologic; D015375:Receptors, Interleukin-2